In 2020.0 DIABETES CARE published article about TYPE-2 DIABETES-MELLITUS; ADD-ON THERAPY; SGLT2 INHIBITORS; TOLERABILITY; METFORMIN in [Jabbour, Serge A.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Frias, Juan P.] Natl Res Inst, Los Angeles, CA USA; [Ahmed, Azazuddin] Apex Med Res, Chicago, IL USA; [Hardy, Elise] AstraZeneca, Gaithersburg, MD USA; [Choi, Jasmine] Statum Res, Irvine, CA USA; [Sjostrom, C. David] AstraZeneca, Gothenburg, Sweden; [Guja, Cristian] Carol Davila Univ Med & Pharm, Bucharest, Romania in 2020.0, Cited 17.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8. Product Details of 64-10-8
OBJECTIVE In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA(1c)], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a 24-week extension period, improvements were sustained at 52 weeks. In this study, we investigated efficacy and safety at 104 weeks after randomization. RESEARCH DESIGN AND METHODS DURATION-8 was a 104-week, multicenter, double-blind, randomized, active-controlled, phase 3 trial. In total, 695 adults (aged >= 18 years) with type 2 diabetes and inadequate glycemic control (HbA(1c)8.0-12.0% [64-108 mmol/mol]) despite stable metformin monotherapy (>= 1,500 mg/day) were randomly assigned (1:1:1) to receive exenatide 2 mg QW plus once-daily dapagliflozin 10 mg, exenatide QW plus placebo, or dapagliflozin plus placebo. All 104-week evaluations were exploratory. RESULTS At week 104, 431 (62.0%) patients completed treatment. The adjusted least squares mean change (SE) from baseline to week 104 in HbA(1c)was greater with exenatide QW plus dapagliflozin (-1.70% [0.11]) versus exenatide QW plus placebo (-1.29% [0.12];P= 0.007) and dapagliflozin plus placebo (-1.06% [0.12];P< 0.001). Clinically relevant changes in FPG, 2-h PPG, weight, and SBP were also observed with exenatide QW plus dapagliflozin. There were no unexpected safety findings, and exenatide QW plus dapagliflozin was well tolerated, with no episodes of major hypoglycemia. CONCLUSIONS In this exploratory analysis, among those individuals who completed the trial without rescue therapy, there was clinically relevant efficacy over 2 years with exenatide QW plus dapagliflozin, with no unexpected safety findings. Bye, fridends, I hope you can learn more about C7H8N2O, If you have any questions, you can browse other blog as well. See you lster.. Product Details of 64-10-8
Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem